Brigatinib CAS No. 1197953-47-1 Pharmaceutical Intermediates
overview
Brigatinib is an innovative medication primarily used in the treatment of ALK-positive non-small cell lung cancer (NSCLC). It works by selectively inhibiting the ALK protein, which is responsible for the growth and spread of cancer cells.
This targeted approach not only enhances the efficacy of the treatment but also minimizes the side effects commonly associated with traditional chemotherapy.
Physical and Chemical Properties
- Stability: Brigatinib exhibits excellent stability under standard laboratory conditions, ensuring reliable results in experimental settings.
- Purity: Our product boasts a high level of purity, typically exceeding 98%, which is crucial for both research and clinical applications.
- Storage Conditions: To maintain its integrity, Brigatinib should be stored in a cool, dry place, away from light and moisture.
1. Potent Activity: Brigatinib has demonstrated superior efficacy in clinical trials, showing significant tumor reduction in patients with ALK-positive NSCLC.
2. Resistance Management: It is effective against various ALK mutations, including those that confer resistance to other treatments, providing a valuable option for patients who have exhausted other therapies.
3. Convenient Dosing: The oral formulation of Brigatinib allows for easy administration, improving patient compliance and convenience.
Brigatinib is compatible with a wide range of laboratory instruments and consumables, Our product can be utilized in various applications, including:
- Cell Culture: Brigatinib can be used in cell culture experiments to study its effects on ALK-positive cancer cell lines.
- In Vivo Studies: Researchers can incorporate Brigatinib into animal models to evaluate its therapeutic potential and pharmacokinetics.
- Analytical Techniques: The compound can be analyzed using techniques such as HPLC, LC-MS, and NMR, providing valuable insights into its chemical behavior and interactions.
In conclusion, As a leading foreign trade company, we are committed to providing high-quality Brigatinib to our clients worldwide. Our product is backed by rigorous quality control processes and a robust supply chain, ensuring that you receive the best possible product for your research and clinical needs. With our expert support and commitment to excellence, we aim to be your trusted partner in advancing cancer research and treatment.
For more information about Brigatinib and how it can benefit your research or clinical practice, please contact us today. We look forward to collaborating with you in the fight against cancer.